<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cell growth and viability are dependent on the function of the multicatalytic proteinase complex (proteasome), a multisubunit particle that affects progression through the mitotic cycle by degradation of cyclins </plain></SENT>
<SENT sid="1" pm="."><plain>Exposure of rodent fibroblasts and human lymphoblasts in culture to benzyloxycarbonyl-<z:chebi fb="0" ids="32630">leucyl</z:chebi>-<z:chebi fb="0" ids="32630">leucyl</z:chebi>-phenylalaninal (Z-LLF-<z:chebi fb="0" ids="29327">CHO</z:chebi>), a cell-permeable peptidyl <z:chebi fb="1" ids="17478">aldehyde</z:chebi> inhibitor of the chymotrypsin-like activity of the proteasome, resulted in the induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a rapid, dose-dependent fashion </plain></SENT>
<SENT sid="2" pm="."><plain>Fibroblasts transformed with ras and myc, lymphoblasts transformed by c-myc alone, and a Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell line that overexpresses c-Myc were up to 40-fold more susceptible to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> than were either primary rodent fibroblasts or immortalized nontransformed human lymphoblasts, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>To determine whether such preferential <z:mpath ids='MPATH_3'>apoptosis</z:mpath> could impact upon <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo, toxicological studies were performed in mice with <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> and showed that mice tolerated single interscapular doses of Z-LLF-<z:chebi fb="0" ids="29327">CHO</z:chebi> without unacceptable toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>Severe combined immunodeficient mice bearing s.c </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in the flank were treated interscapularly with Z-LLF-<z:chebi fb="0" ids="29327">CHO</z:chebi> or a comparable dose of the peptidyl alcohol (Z-LLF-OH), which does not induce proteasome inhibition or <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Single doses of Z-LLF-<z:chebi fb="0" ids="29327">CHO</z:chebi> induced statistically significant (P &lt; 0.0001) early <z:mp ids='MP_0010537'>tumor regression</z:mp> and a significant (P &lt; 0.0001) delay in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens revealed <z:mp ids='MP_0006042'>increased apoptosis</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from mice treated with Z-LLF-<z:chebi fb="0" ids="29327">CHO</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>These results, showing a 42% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0001510'>growth delay</z:hpo>, indicate that <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> have the potential of curbing the growth of a c-myc-related <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>